Our research broadly involves the identification, significance, and function of genetic mutations in pediatric leukemia. We develop and use laboratory based assays to conduct cohort studies in primary human cells that interrogate the role of specific genetic mutations in human leukemia. We focus on integrating novel mutations into clinical use (e.g. assessing prognostic significance or minimal residual disease) as well as yield insights that lead to more scientific questions about the pathogenesis and mechanisms of disease. Recent areas of interest have focused on using phosphoflow signaling tools to dissect the aberrant signal transduction pathways that arise in response to mutations in the Ras pathway in juvenile myelomonocytic leukemia (JMML). In addition, we have begun to sort stem and progenitor cells to further interrogate the population of cells that initiate and maintain JMML.